Skip to main content
×
Home

Healthcare resource utilization and cost in dementia: are there differences between patients screened positive for dementia with and those without a formal diagnosis of dementia in primary care in Germany?

  • Bernhard Michalowsky (a1), Tilly Eichler (a1), Jochen René Thyrian (a1), Johannes Hertel (a1), Diana Wucherer (a1), Wolfgang Hoffmann (a1) (a2) and Steffen Flessa (a3)...
Abstract
ABSTRACT Background:

It is well-known that dementia is undiagnosed, resulting in the exclusion of patients without a formal diagnosis of dementia in many studies. Objectives of the present analyses were (1) to determine healthcare resource utilization and (2) costs of patients screened positive for dementia with a formal diagnosis and those without a formal diagnosis of dementia, and (3) to analyze the association between having received a formal dementia diagnosis and healthcare costs.

Method:

This analysis is based on 240 primary care patients who screened positive for dementia. Within the baseline assessment, individual data about the utilization of healthcare services were assessed. Costs were assessed from the perspective of insurance, solely including direct costs. Associations between dementia diagnosis and costs were evaluated using multiple linear regression models.

Results:

Patients formally diagnosed with dementia were treated significantly more often by a neurologist, but less often by all other outpatient specialists, and received anti-dementia drugs and day care more often. Diagnosed patients underwent shorter and less frequent planned in-hospital treatments. Dementia diagnosis was significantly associated with higher costs of anti-dementia drug treatment, but significantly associated with less total medical care costs, which valuated to be € 5,123 compared, to € 5,565 for undiagnosed patients. We found no association between dementia diagnosis and costs of evidence-based non-medication treatment or total healthcare cost (€ 7,346 for diagnosed vs. € 6,838 for undiagnosed patients).

Conclusion:

There are no significant differences in total healthcare cost between diagnosed and undiagnosed patients. Dementia diagnosis is beneficial for receiving cost-intensive anti-dementia drug treatments, but is currently insufficient to ensure adequate non-medication treatment for community-dwelling patients.

Copyright
Corresponding author
Correspondence should be addressed to: Bernhard Michalowsky, German Centre for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Ellernholzstrasse 1-2, Greifswald D-17487, Germany. Phone: +49 3834 86 7591. Email: bernhard.michalowsky@dzne.de.
Footnotes
Hide All

The original version of this article was published with an author incorrectly omitted. A notice detailing this has been published and the error rectified in the online and print PDF and HTML copies.

Footnotes
References
Hide All
Borson S. et al. (2013). Improving dementia care: the role of screening and detection of cognitive impairment. Alzheimers & Dementia, 9, 151159.
Boustani M., Peterson B., Hanson L., Harris R. and Lohr K. N. (2003). Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive services task force. Annals of Internal Medicine, 138, 927937.
Calabrese P. and Kessler J. (2000). Screening for cognitive impairment in dementia - the DemTect procedure. European Neuropsychopharmacology, 10, 369.
Connolly A., Gaehl E., Martin H., Morris J. and Purandare N. (2011). Underdiagnosis of dementia in primary care: variations in the observed prevalence and comparisons to the expected prevalence. Aging & Mental Health, 15, 978984.
Desgagne A., Castilloux A. M., Angers J. F. and LeLorier J. (1998). The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics, 13, 487497.
Dreier A., Thyrian J. R. and Hoffmann W. (2011). Dementia care manager in der ambulanten demenzversorgung: entwicklung einer innovativen qualifizierung für pflegefachkräfte. Pflege & Gesellschaft, 16, 5364.
Eisele M. et al. (2010). Utilization patterns of ambulatory medical care before and after the diagnosis of dementia in Germany - results of a case-control study. Dementia and Geriatric Cognitive Disorders, 29, 475483.
Eichler T. et al. (2013). Dementia care management: going new ways in ambulant dementia care within a GP-based randomized controlled intervention trial. International Psychogeriatrics, 26, 247256.
Eichler T. et al. (2014). Rates of formal diagnosis in people screened positive for dementia in primary care: results of the DelpHi-trial. Journal of Alzheimers Disease, 42, 451458.
Federal Statistical Office (2013a). Grunddaten der Krankenhäuser 2012. Wiesbaden: Statistisches Bundesamt.
Federal Statistical Office (2013b). Kostennachweis der Krankenhäuser 2012. Wiesbaden: Statistisches Bundesamt.
Federal Statistical Office (2013c). Pflegestatistik 2011- Pflege im Rahmen der Pflegeversicherung Deutschlandergebnisse. Wiesbaden: Statistisches Bundesamt.
Fendrich K. and Hoffmann W. (2007). More than just aging societies: the demographic change has an impact on actual numbers of patients. Journal of Public Health, 15, 345351.
Gauggel S. and Birkner B. (1999). Validity and reliability of a German version of the Geriatric Depression Scale (GDS). Zeitschrift fur Klinische Psychologie - Forschung und Praxis, 28, 1827.
German Association for Psychiatry, Psychotherapy and Psychosomatics & German Association for Neurology (DGN) (2009). S-3 Leitlinie “Demenzen”. Available at: http://www.dgppn.de/fileadmin/user_upload/_medien/download/pdf/kurzversion-leitlinien/s3-leitlinie-demenz-lf.pdf; last accessed 1 November 2014.
Handels R. L. H., Wolfs C. A. G., Aalten P., Verhey F. R. J. and Severens J. L. (2013). Determinants of care costs of patients with dementia or cognitive impairment. Alzheimer Disease & Associated Disorders, 27, 3036.
Hindmarch I., Lehfeld H., E. J. P. and Erzigkeit H. (1998). The bayer activities of daily living scale (B-ADL). Dementia and Geriatric Cognitive Disorders, 9, 2026.
Hoffmann F., Van den Bussche H., Glaeske G. and Kaduszkiewicz H. (2010). Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany. International Clinical Psychopharmacology, 25, 2936.
Kaduszkiewicz H., Wiese B., Steinmann S., Schon G., Hoffmann F. and Van den B. H. (2014). Diagnosing and diagnosis coding of dementias in claims data from German statutory health insurance. Psychiatrische Praxis, 41, 319323.
Kessler J., Markowitsch H. J. and Denzler P. (1990). Mini-Mental-Status-Test (MMST) [German Version]. Göttingen, Beltz Test GmbH.
Krauth C., Hessel F., Hansmeier T., Wasem J., Seitz R. and Schweikert B. (2005). Empirical standard costs for health economic evaluation in Germany – a proposal by the working group methods in health economic evaluation. Gesundheitswesen, 67, 736746.
Leicht H. et al. (2011). Net costs of dementia by disease stage. Acta Psychiatrica Scandinavica, 124, 384395.
Michalowsky B. et al. (2014). Medication cost of persons with dementia in primary care in germany. Journal of Alzheimers Disease, 42, 949958.
Prince M., Bryce R. and Ferri C. (2011). World Alzheimer Report 2011 - The benefits of early diagnosis and intervention. Alzheimer's Disease International (ADI), London.
Sano M., Wilcock G. K., Van B. B. and Kavanagh S. (2003). The effects of galantamine treatment on caregiver time in Alzheimer's disease. International Journal of Geriatric Psychiatry, 18, 942950.
Schwarzkopf L. et al. (2011). Costs of care for dementia patients in community setting: an analysis for mild and moderate disease stage. Value in Health, 14, 827835.
Scientific Institute of the AOK (2013). GKV-Arzneimittelindex. Available at: http://www.wido.de/gkvarzneimittelind.html; last accessed 1 November 2014.
Thyrian J. R. et al. (2012). Life- and person-centred help in Mecklenburg-western pomerania, Germany (DelpHi): study protocol for a randomised controlled trial. Trials, 13, 56.
Vergütungslisten/Vergütungsvereinbarungen der Kassenverbände (2014). Heilmittel-Einzelpreise in EURO nach Kassenart – Stand Mai 2014. Available at: http://www.kvwl.de/arzt/verordnung/hhm/heilmittel/heilmittelpreise.pdf; last accessed 1 November 2014.
Wimo A., Jonsson L., Bond J., Prince M. and Winblad B. (2013). The worldwide economic impact of dementia 2010. Alzheimers Dement, 9, 111.
Wimo A., Jonsson L. and Winblad B. (2006). An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dementia and Geriatric Cognitive Disorders, 21, 175181.
Wimo A., Winblad B., Stoffler A., Wirth Y. and Mobius H. J. (2003). Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics, 21, 327340.
World Health Organization and Alzheimer's Disease International (2012). Dementia: a public health priority. Available at: http://apps.who.int/iris/bitstream/10665/75263/1/9789241564458_eng.pdf?ua=1; last accessed 1 November 2014.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Type Description Title
WORD
Supplementary Materials

Michalowsky supplementary material S1
Supplementary Table

 Word (23 KB)
23 KB
WORD
Supplementary Materials

Michalowsky supplementary material S2
Supplementary Table

 Word (23 KB)
23 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 10
Total number of PDF views: 116 *
Loading metrics...

Abstract views

Total abstract views: 459 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 19th November 2017. This data will be updated every 24 hours.